西班牙新生儿镰状细胞病筛查的成本效益分析数据集

数据集获取（Figshare）

• 源站标题：Cost-effectiveness analysis of newborn screening for sickle-cell disease in Spain
• DOI：10.6084/m9.figshare.3204466
• 发布日期：2016-04-28
• 文件数：3 个
• 文件总体积：43.88 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost_effectiveness_analysis_of_newborn_screening_for_sickle_cell_disease_in_Spain/3204466

命令行下载

curl -L -o "Suppl_Table_1.docx" "https://ndownloader.figshare.com/files/5029540"
curl -L -o "Suppl_Table_2.docx" "https://ndownloader.figshare.com/files/5029543"
curl -L -o "Suppl_Table_3.docx" "https://ndownloader.figshare.com/files/5029546"

文件清单

• Suppl_Table_1.docx（14.21 KB）
• Suppl_Table_2.docx（16.09 KB）
• Suppl_Table_3.docx（13.58 KB）

文件总体积 43.88 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objectives: This study assesses the cost-effectiveness of adding sickle-cell disease (SCD) to the Spanish newborn screening (NBS) program, and explores the sensitivity of the results to key model parameters.
Methods: A discrete event simulation model was developed that compared NBS for SCD versus clinical detection. The model followed a simulated cohort of newborns for 10 years, and estimated the impact in costs and life expectancy of prophylactic treatments established after early detection. Probabilistic, one-way and two-way sensitivity analysis were performed.
Results: NBS was found to be more costly and more effective than clinical detection of SCD. The estimated incremental cost per life year (LY) gained was 34,169.46 €/LY. This result was very sensitive to the cost of the screening test, the birth prevalence and the proportion of severe cases among the affected children.
Conclusions: There is uncertainty regarding the cost-effectiveness of NBS for SCD in the Spanish context. Our base case estimate of the cost per LY gained lies near the 30,000€/LY commonly cited in Spain.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.3204466（source: https://tandf.figshare.com/articles/dataset/Cost_effectiveness_analysis_of_newborn_screening_for_sickle_cell_disease_in_Spain/3204466）。